Zim Laboratories Ltd.
132.12
INR
-0.17
(-0.13%)
ISIN
INE518E01015
Return %
Stock
S&P 500
1Y
91.48
14.20
3Y
11.26
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Anwar Siraj Daud
- Full Time Employees
- 632
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- Sadoday Gyan Nagpur MA India 440 013
- IPO Date
- Jun 8, 2018
- Website
- zimlab.in
- Similar Companies
- Business
- ZIM Laboratories Limited (ZIMLAB.NS) is an India-based pharmaceutical company specializing in the research, development, manufacturing, and marketing of innovative dosage forms and novel drug delivery systems. The company offers a diverse portfolio of products including mucoadhesive buccoadhesive tablets under the Zimacef brand; prefilled syringes and single-dose sachets for effervescent formulations; dry syrups, dispersible tablets, chewable tablets, and orally disintegrating strips (ODT); multiparticulate systems such as pellets, granules, mini-tablets, and microcapsules; and specialized nutrition products like ready-to-drink oral nutrition supplements, powder sachets, and fortified complementary foods for maternal and child health. ZIM provides end-to-end contract development and manufacturing organization (CDMO) services encompassing formulation development, scale-up, process validation, stability studies, and regulatory support for generics and differentiated generics across therapeutic areas such as anti-infectives, gastro-intestinal, anti-diabetic, cardiovascular, and nutraceuticals. Founded in 1989 and headquartered in Nagpur, India, ZIM operates primarily in the pharmaceutical and nutraceutical sectors, targeting generic pharmaceutical companies, consumer healthcare brands, and pediatric nutrition markets in over 60 countries across Asia, Africa, Latin America, Europe, and the Middle East through a network of subsidiaries and strategic partnerships. The company maintains three cGMP-compliant manufacturing facilities in India certified by regulatory bodies including USFDA, WHO, and EU-GMP, focusing on affordable healthcare solutions via technology-led innovations like taste-masking and modified-release formulations. In recent developments, ZIM Laboratories completed the acquisition of a majority stake in Medro Pharmaceuticals in early 2024 to bolster its nutraceutical offerings and expand consumer brand presence in India; launched its ZIM Nutrition division in 2023 with new maternal and pediatric nutrition products including ZIMVital and pediatric supplements; secured a strategic distribution partnership with Softigel for Latin American markets in 2024; raised INR 50 crore through a preferential allotment in late 2023 to fund capacity expansion and R&D; and obtained USFDA approval for its Nagpur facility's oral solids line in mid-2024, enabling entry into regulated markets. These initiatives reflect ZIM's strategic shift toward nutrition-led growth and global CDMO expansion, with nutraceuticals now comprising over 25% of revenues amid a 20%+ year-over-year topline growth in FY2025.